Search Results

for the dialysis market and as Procrit by OrthoBiotech for other markets, including cancer and HIV/AIDS. In 1993, the FDA added an indication for cancer-related anemia as a label supplement for epoetin alfa (Epogen/Procrit), specifying that the

value of using intravenous (IV) iron for cancer-related anemia. Preventing FN FN, when brief and uncomplicated, has a low-risk mortality. However, the risk of death may increase to more than 20% in patients with major comorbidities. 1 Giving lower

care. Second, a report discussing the clinical and operational challenges related to the management of cancer-related anemia details an NCCN Member Institution's initiative to reduce the use of blood products and also includes results from 3 different

an increase in hemoglobin levels in patients with cancer-related anemia and, in those who were also receiving chemotherapy, treatment with erythropoiesis-stimulating agents (ESAs) was associated with a reduction in red cell transfusions. In 1989, the

systemic, quantitative review . Cancer 2001 ; 91 : 2214 – 2221 . 48 Blohmer JU Dunst J Harrison L . Cancer-related anemia: biological findings, clinical implications and impact on quality of life . Oncology 2005 ; 1 : 12 – 21 . 49

combining multiple routine laboratory variables. Cancer-related anemia is due to multiple etiologies, including chemotherapy-induced myelosuppression, blood loss, functional iron deficiency, erythropoietin deficiency due to renal disease, marrow involvement

. Gilreath JA Stenehjem DD Rodgers GM . Diagnosis and treatment of cancer-related anemia . Am J Hematol 2014 ; 89 : 203 – 212 . 7. Pfeiffer CM Johnson CL Jain RB . Trends in blood folate and vitamin B-12 concentrations in the United States

Goss G . Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review . Cancer 2001 ; 91 : 2214 – 2221 . 92. Blohmer JU Dunst J Harrison L . Cancer-related anemia: biological findings

-label study by Henry et al., 77 187 patients with cancer-related anemia receiving chemotherapy and epoetin alfa were randomized to no iron, oral ferrous sulfate 3 times daily, or weekly intravenous ferric gluconate. Intravenous iron produced a significantly